Medications for Eating Disorders: What Evidence Supports
Author: Angela Bogdanova · Published: October 10, 2026 · Editorial Policy
Research cluster: Eating Disorders & Disordered Eating · Written by Artificial Sapiens
Medication can reduce certain eating-disorder symptoms, but the benefits differ substantially by diagnosis, age, medical condition, and the particular outcome being measured. In the United States, fluoxetine has an eating-disorder indication for bulimia nervosa in adults, and lisdexamfetamine has an indication for moderate to severe binge-eating disorder in adults. No medication is approved specifically to treat anorexia nervosa. Some other medications have encouraging trial results but remain off-label, while evidence for avoidant/restrictive food intake disorder (ARFID), pica, and rumination disorder is much thinner. These distinctions are central to the American Psychiatric Association practice guideline and the 2023 World Federation of Societies of Biological Psychiatry guideline.
This article reviews what medications can and cannot be expected to accomplish, the quality of evidence for individual disorders, treatment combinations, age-specific considerations, and the safety questions that should shape every prescribing decision. It concerns professionally supervised clinical treatment, not self-prescribing or medication-based weight control.
Which eating disorders have evidence-supported medications?
The clearest distinction concerns the target condition. For bulimia nervosa, fluoxetine reduces binge-eating and purging behaviors in adults and has regulatory approval for that indication. For binge-eating disorder (BED), lisdexamfetamine reduces binge-eating frequency in appropriately selected adults, while some antidepressants and topiramate have supportive evidence with important limitations. For anorexia nervosa, studies of olanzapine suggest a modest improvement in weight restoration in some adults, but changes in core eating-disorder thoughts and longer-term recovery are less consistently demonstrated. For ARFID and other feeding or eating disorders, published medication studies are predominantly small, observational, or indirect. These conclusions follow from the WFSBP systematic guideline review, the APA guideline, and later comparative syntheses.
A useful clinical summary is that medication evidence is strongest for particular adult bulimia and binge-eating symptoms, narrower in anorexia, and preliminary for several other diagnoses. Evidence of fewer binge episodes does not, by itself, establish recovery in body-image distress, dietary rigidity, interpersonal functioning, or relapse risk. Similarly, drug-associated weight change is a separate outcome from improvement in an eating disorder.
Medication compared with psychotherapy and nutritional treatment
The intended role of a drug must be established in the treatment plan. Psychotherapies can address patterns of restriction, loss of control, avoidance, compensatory behavior, distorted beliefs, and difficulties that sustain the illness. Nutrition and medical care address inadequate intake, nutritional deficiencies, dehydration, and associated physical instability. Medication may add benefit for particular symptoms or co-occurring conditions. The APA guideline recommends specialized psychological treatment for anorexia, bulimia, and BED, and the NICE NG69 recommendations advise against offering medication as the sole treatment for these disorders.
This distinction matters even when a drug produces a measurable benefit in a randomized trial. A participant may report fewer binge episodes yet continue to struggle with shame, secrecy, rigid eating rules, food insecurity, or a coexisting psychiatric condition. A person with anorexia may experience medication-associated weight change while remaining medically unstable or intensely distressed about eating. Effective care evaluates physical safety, psychological symptoms, functional recovery, and the individual’s goals together. For the broader comparison of psychotherapy, nutrition, family support, and clinical monitoring, see Eating Disorder Treatment: Evidence-Based Therapies and Care.
Fluoxetine for bulimia nervosa
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and the best-established pharmacologic option for adult bulimia nervosa. Trials demonstrated reductions in the frequency of binge eating and vomiting compared with placebo, leading to its FDA-recognized bulimia indication. The official fluoxetine prescribing information explains the trial basis for this indication. The APA guideline recommends eating-disorder-focused cognitive behavioral therapy (CBT) with a serotonin reuptake inhibitor for adults, either from the outset or when psychotherapy alone has produced insufficient early improvement.
Medication decisions also depend on what is happening medically. Recurrent purging can produce dehydration and electrolyte abnormalities that change the risks of prescribing. A clinician may request medical assessment, electrolyte testing, and an electrocardiogram depending on symptoms, medication interactions, and cardiac concerns. Fluoxetine can cause gastrointestinal symptoms, changes in sleep, sexual side effects, agitation, and medication interactions; antidepressant treatment requires monitoring for emerging suicidality in younger patients. Comorbid bipolar disorder also requires careful assessment before antidepressant treatment. These risks are evaluated in the context of NICE medication safety guidance for eating disorders.
Fluoxetine’s FDA indication applies to adult bulimia nervosa. Its use in adolescents with bulimia is a separate clinical decision, often off-label, with a different evidence base and developmental context. Families and clinicians should distinguish a recommendation for adults from evidence applicable to younger patients. For adolescents, specialist psychological and family-based approaches retain a central role.
What about other antidepressants for bulimia?
Several antidepressant classes have been studied for bulimia, including other SSRIs and earlier tricyclic medications. Some trials suggest reductions in binge–purge symptoms, but fluoxetine has the strongest recognized evidence and regulatory status. The WFSBP guideline also discusses topiramate as an evidence-supported off-label treatment for bulimia. That is a recommendation based on trial findings, not an FDA approval for eating disorders.
Medication selection should account for seizure risk, cardiac effects, weight and appetite effects, cognitive side effects, pregnancy considerations, and comorbid symptoms. Tricyclic antidepressants can create substantial toxicity concerns, especially in people with dehydration or electrolyte abnormalities. The fact that a drug treats depression generally does not demonstrate that it effectively treats bulimia. Prescribing must be guided by the disorder, the specific medication, and the patient’s clinical status.
Binge-eating disorder: lisdexamfetamine
Lisdexamfetamine is an FDA-approved central nervous system stimulant for moderate to severe BED in adults. Randomized trials support reductions in binge-eating frequency for selected adult participants. Its efficacy has been included in 2025 and 2026 network meta-analyses. This evidence does not make lisdexamfetamine an appropriate medication for every instance of overeating, emotional eating, loss-of-control eating, or bulimia. BED is a specific diagnosis established through clinical assessment.
The 2025 FDA Vyvanse label specifies the adult BED indication and states that the medication is not indicated for weight loss. It carries a boxed warning about abuse, misuse, and addiction. Possible adverse effects include insomnia, anxiety, elevated heart rate or blood pressure, appetite suppression, and gastrointestinal problems. Clinicians review cardiovascular history, substance-use vulnerability, other psychiatric conditions, interacting medications, and the possibility of restrictive eating before prescribing.
BED treatment is directed toward reducing distressing episodes, improving eating patterns and functioning, and supporting sustained recovery. Body weight is not a substitute measure for BED severity or treatment success. The APA guideline places eating-disorder-focused CBT or interpersonal therapy among recommended treatments and suggests an antidepressant or lisdexamfetamine for adults who prefer medication or have not responded sufficiently to psychotherapy alone. The NICE guideline emphasizes psychological treatment and does not recommend medication as the sole intervention.
Other medications for binge-eating disorder
Topiramate, an antiseizure medication, has shown reductions in binge-eating frequency in randomized trials and meta-analyses. A 2025 network meta-analysis found promising effects on binge episodes and remission, while a 2026 comparative analysis found reductions in binge frequency with both topiramate and lisdexamfetamine. Topiramate is used off-label for BED in the United States. Potential harms include cognitive slowing, concentration and memory difficulties, tingling sensations, mood effects, and important reproductive safety concerns. Trial efficacy must be weighed against adverse effects and discontinuation.
SSRIs and some other antidepressants may improve binge frequency and coexisting mood or anxiety symptoms, although study results and effect sizes vary. An antidepressant used for BED is not automatically FDA-approved for BED. The APA guideline allows antidepressant treatment in adults when it fits clinical needs and preferences; choice depends on psychiatric history, prior response, adverse effects, and the whole treatment plan.
Trials have also investigated other agents, including naltrexone-containing approaches. In the 2026 network meta-analysis, naltrexone/bupropion did not demonstrate a statistically clear reduction in binge-eating frequency compared with placebo. A medication’s effect on weight in a study must not be misrepresented as proof that it treats BED. Results in short-duration trials may not predict sustained recovery.
Anorexia nervosa: why medications have a smaller role
Anorexia nervosa involves a complex interaction of restrictive eating, fear or beliefs concerning weight and shape, nutritional compromise, and major medical risk. Psychological treatment and nutritional rehabilitation under medical supervision are central to care. No medication has FDA approval specifically for treating anorexia nervosa, and antidepressants have not consistently demonstrated effectiveness for its central psychopathology or for restoring weight during acute undernutrition. The NICE guidance advises that medication should not be used as the sole treatment.
Olanzapine is the medication with the most notable, though bounded, adult evidence. In a 16-week randomized trial of 152 adults, the olanzapine group experienced a greater rate of BMI increase than the placebo group, while the study did not demonstrate a significant advantage on its measure of obsessionality. The WFSBP guideline accordingly gives olanzapine a limited recommendation tied mainly to weight outcomes, with less clarity about eating-disorder thoughts and longer-term remission.
Olanzapine can cause sedation, metabolic changes, changes in glucose and lipids, and other adverse effects. It requires individualized monitoring. A modest trial effect does not justify using medication as a replacement for clinical nutrition, specialist psychotherapy, physical monitoring, or family support. Evidence from predominantly adult trials should not be casually generalized to children, medically unstable adolescents, or patients with different clinical presentations.
Atypical anorexia and OSFED
Atypical anorexia nervosa falls within other specified feeding or eating disorder (OSFED) in DSM-5-TR. Someone can have substantial restrictive eating and the psychological features of anorexia while remaining at a weight that would not meet the low-weight criterion for anorexia nervosa. Rapid weight loss, malnutrition, bradycardia, orthostatic symptoms, and other complications may be significant at different body sizes. Medication choices therefore require clinical evaluation of behaviors, weight trajectory, nutritional status, and physiology, rather than a BMI threshold alone.
There are few medication trials specifically designed for atypical anorexia, purging disorder, and other OSFED presentations. NICE advises clinicians to consider treatments used for the eating disorder that the OSFED presentation most closely resembles. That recommendation is a clinical framework, not proof that the efficacy data can be transferred unchanged across diagnostic categories. A person with an OSFED presentation may also need treatment for a coexisting depression or anxiety disorder, but the medication target and evidence should be documented separately.
ARFID: an emerging pharmacotherapy evidence base
Avoidant/restrictive food intake disorder can involve sensory sensitivity, low interest in eating, fear of aversive consequences such as choking, or a combination of these patterns. Its assessment should consider nutritional adequacy, developmental and sensory profiles, medical conditions affecting swallowing or digestion, and functional impairment. The treatment goals differ from the body-shape and weight-driven concerns characteristic of anorexia and bulimia.
Medication research for ARFID is much less developed. Small studies and clinical reports have explored agents such as mirtazapine, cyproheptadine, and olanzapine for selected symptoms, appetite, anxiety, or nutritional support. None is an FDA-approved treatment specifically for ARFID, and results do not support a universal medication regimen. The WFSBP systematic guideline characterizes evidence for ARFID, pica, and rumination disorder as sparse. Medical and nutritional assessment, appropriate psychological or behavioral treatment, and individualized family involvement remain foundational.
The same restraint applies to pica and rumination disorder. Treating iron deficiency or another medical contributor to pica, when present, addresses that contributor; it is not the same as demonstrating a drug cures pica. Rumination disorder often requires behavioral treatment and a medical differential evaluation. Medication studies of gastroesophageal disorders should not be generalized automatically to primary rumination disorder.
Orthorexia and other emerging labels
Orthorexia is discussed in research as a pattern of rigid, distressing preoccupation with healthy or pure eating, but it is not an independent DSM-5-TR or ICD-11 eating-disorder diagnosis. There is no validated medication treatment established specifically for orthorexia. The clinician instead evaluates the person’s actual symptoms and whether they meet criteria for another recognized disorder, along with nutritional and functional effects.
Terms such as food addiction and emotional eating can also describe experiences or theoretical frameworks without automatically identifying a medication-responsive eating disorder. A drug trial conducted in clinically diagnosed BED should not be presented as evidence for every popular label involving food. The distinction between symptom, screening score, clinical diagnosis, and comorbidity helps prevent inappropriate prescriptions.
Can medications treat depression, anxiety, OCD, or ADHD alongside an eating disorder?
Yes. A person may have both an eating disorder and a clinically diagnosed condition for which medication has an established independent role. The prescriber should identify which condition is being treated and decide whether medication effects could complicate eating-disorder recovery. For example, stimulant treatment of ADHD can suppress appetite, which requires special attention when restriction or inadequate intake is present. Depression and anxiety may improve partly through nutritional restoration; persistent disorders may require their own treatment.
Medication safety can change dramatically with malnutrition, purging, and dehydration. NICE guidance specifically calls for consideration of medication effectiveness, adherence, physical complications, and electrocardiogram monitoring when cardiac-risk medications are involved. A psychiatric prescription that was previously tolerated may need reassessment as the person’s physiology changes. Care is often coordinated among the eating-disorder clinician, prescribing psychiatrist or primary-care clinician, and other specialists.
Which medications require particular caution?
Bupropion deserves an especially clear warning: official U.S. prescribing information lists a current or prior diagnosis of anorexia nervosa or bulimia nervosa as a contraindication because of seizure risk. This matters even when bupropion is being considered for a different condition, such as depression or smoking cessation. Anyone with a relevant eating-disorder history should disclose it to the prescriber.
Other medication risks depend on the individual drug and the patient's condition. Stimulants may affect pulse, blood pressure, sleep, and appetite. Certain antidepressants and antipsychotics require assessment of cardiac or metabolic risks. Some medications may interact with substances, over-the-counter products, or existing prescriptions. Electrolyte abnormalities related to purging can increase vulnerability to cardiac events. Risk assessment is a clinical process, not a list of medications to avoid without individualized review.
What about GLP-1 medications for binge eating?
GLP-1 receptor agonists have attracted attention because of their metabolic and appetite-related effects. Small studies and early reviews have explored whether some agents might reduce binge-eating symptoms. These findings are preliminary for eating-disorder treatment and should not be equated with FDA approval to treat BED, bulimia, anorexia, or ARFID. The 2025 systematic review of newer pharmacologic approaches describes promising observations alongside methodological limitations and the need for stronger trials.
A person may receive a GLP-1 medication for a separate approved medical indication while having a current or past eating disorder. In that situation the key questions include nutritional adequacy, restriction or purging history, gastrointestinal effects, psychological responses to appetite change, and coordination between prescribers and the eating-disorder team. An effect on appetite or body weight is not a validated measure of eating-disorder recovery.
Children and adolescents: a different evidence and consent context
Medication evidence is disproportionately drawn from adult studies. The FDA bulimia indication for fluoxetine concerns adults, as does the BED indication for lisdexamfetamine. A drug may have a pediatric indication for another condition, but that does not transfer to treating an eating disorder in young patients. Growth, pubertal development, family context, nutrition, school functioning, and safeguarding shape pediatric clinical decisions.
For adolescents with anorexia, the APA practice guideline recommends eating-disorder-focused family-based treatment when an involved caregiver is available. For bulimia, age-appropriate family and eating-disorder-focused psychological treatments remain central. Specialist prescribers may treat co-occurring conditions, but the evidence for direct pharmacotherapy of the eating disorder itself must be described accurately to the young person and caregivers.
Pregnancy, lactation, and reproductive health
Pregnancy planning may change the balance of risks from psychotropic medication, nutritional compromise, and untreated psychiatric illness. Some medicines have important reproductive contraindications or risks, while abrupt discontinuation of effective psychiatric treatment can also cause harm. Decisions require individualized discussion with the treating prescriber and obstetric team, considering the medication, gestational stage, illness severity, and available alternatives.
For those who might become pregnant, medication review should cover potential teratogenic effects, contraception where applicable, and the safety of ongoing treatment. Nutrition, medical monitoring, and treatment of the eating disorder remain essential throughout the perinatal period. The NICE eating-disorder guideline recommends coordinated attention to mental health and nutritional needs during pregnancy and afterward.
How are medications evaluated and monitored?
Before prescribing, a clinician establishes a diagnostic formulation and reviews the person's eating behavior, nutritional history, weight trajectory, current physical health, co-occurring psychiatric symptoms, and medication history. Depending on the presentation, assessment may include vital signs, orthostatic measurements, relevant laboratory testing, electrolytes, hydration, and cardiac evaluation. The value and urgency of these assessments are determined clinically.
The treatment team should then agree on outcomes that match the diagnosis. In bulimia, frequency and distress of binge–purge behavior and broader psychological functioning matter. In BED, binge frequency, distress, food-related functioning, and quality of life are more informative than weight alone. In anorexia, nutritional rehabilitation, physiologic stability, cognitive symptoms, functioning, and sustained recovery require attention. Medication adverse effects, adherence, and interaction with psychotherapy are reviewed throughout treatment.
A medication trial may be stopped or changed when benefits are inadequate, adverse effects are unacceptable, medical risk increases, or another treatment becomes more appropriate. Stopping or switching prescription medication should be coordinated with the prescriber. Continuous review is particularly important because eating-disorder symptoms and physical vulnerability can fluctuate during recovery.
Medical emergencies and medication safety
Eating disorders can cause dangerous medical complications at many body sizes. Fainting, chest pain, sustained palpitations, severe weakness or confusion, inability to maintain fluids, signs of significant dehydration, or suspected severe electrolyte disturbance warrant urgent medical evaluation. Suicidal intent, overdose, and acute psychiatric crises also require immediate emergency assistance. A person should not wait for a routine medication appointment when acute safety concerns are present.
Rapid nutritional changes after prolonged restriction may also require supervised refeeding and monitoring. Medications cannot substitute for correction of serious malnutrition, assessment of arrhythmia risk, or urgent treatment of physical complications. Clinical seriousness is established by the combination of behavior, recent changes, medical findings, and function, not a single visible body characteristic. See the APA assessment and treatment guideline and NICE medical risk recommendations.
What are the limitations of the medication research?
The strongest medication trials have studied carefully selected adult participants with particular diagnoses over relatively short treatment periods. Participants with severe medical instability, complex comorbidity, or certain safety risks may be excluded. Outcomes such as episode frequency, symptom scale scores, remission, and weight change are not interchangeable, and follow-up after medication withdrawal is often limited.
The 2025 BED network meta-analysis noted inconsistent definitions of remission and incomplete use of validated assessment tools. The 2026 meta-analysis identified substantial variation among studies. Such findings justify cautious conclusions about comparative effectiveness and long-term durability. Evidence in adolescents, men, diverse gender populations, individuals with atypical anorexia, and people with more complex physical conditions remains uneven.
Comparing drugs across separate studies also presents difficulty: different trial designs, participant populations, dose schedules, outcome definitions, and background psychotherapies can change observed effects. For this reason, a statistical ranking in a network meta-analysis should not be interpreted as a universal clinical ranking of medications. Safety, access, patient preference, and the treatment team's experience are essential to decisions.
How to discuss medication with a clinician
A productive conversation begins with the diagnosis being treated and the specific outcome a medication is expected to improve. Ask what research supports that use, whether it is FDA-approved for the particular disorder and age group, how benefit will be monitored, and what alternatives are available. Questions about nutrition, sleep, heart health, other prescriptions, pregnancy plans, and prior eating-disorder symptoms are directly relevant.
It is also reasonable to ask how long a medication will be evaluated before deciding whether it helps, what adverse effects should prompt contact, and how the treatment plan includes psychotherapy and nutritional or medical support. If care involves multiple clinicians, clarify who coordinates medication changes and medical monitoring. Eating Disorder Recovery: Stages, Challenges, and Support discusses the wider process beyond initial symptom reduction.
Frequently asked questions
Is there one medication that treats every eating disorder?
No. FDA-recognized eating-disorder indications differ by diagnosis and age. Fluoxetine is indicated for adult bulimia nervosa, lisdexamfetamine for moderate to severe BED in adults, and anorexia nervosa has no medication specifically approved for its treatment. Other diagnosed eating or feeding disorders generally have much less direct drug evidence. FDA lisdexamfetamine labeling and WFSBP guidance give the relevant distinctions.
Can antidepressants stop binge eating?
Some antidepressants reduce binge eating or related symptoms in selected patients. Fluoxetine has the clearest specific role in adult bulimia; antidepressants may be considered for adults with BED according to clinical circumstances. Response differs across individuals and diagnoses. A prescription for depression cannot be assumed to treat an eating disorder.
Is Vyvanse approved for binge-eating disorder?
Yes, lisdexamfetamine (Vyvanse) is FDA-approved for moderate to severe BED in adults. The label also states it is not indicated for weight loss and warns about abuse, misuse, and addiction. It is a regulated medication requiring professional assessment and monitoring. FDA label.
Is olanzapine a cure for anorexia?
Clinical studies suggest that olanzapine may modestly support weight restoration in some adults, but evidence for changing the central psychological features of anorexia is less conclusive. Nutritional rehabilitation, specialist therapy, and medical care remain necessary. Randomized trial.
Can a person with bulimia take bupropion?
U.S. bupropion prescribing information lists current or previous bulimia nervosa or anorexia nervosa as contraindications because of seizure risk. The prescriber should be informed of any such history, including when the drug is being considered for a separate condition. DailyMed label.
Is topiramate approved for BED or bulimia?
Topiramate has supportive research for reducing certain binge-related behaviors but lacks FDA approval specifically for eating disorders. Adverse effects and reproductive safety concerns can meaningfully limit its use. WFSBP guideline; 2025 systematic review.
Do GLP-1 medications treat eating disorders?
Early studies are exploring effects on binge eating, but GLP-1 medicines are not established as FDA-approved eating-disorder treatments. A medication may be prescribed for an independent metabolic indication, which requires coordinated evaluation if an eating disorder is also present. 2025 research review.
Are medication recommendations the same for teenagers?
No. Trial populations and approved indications matter. Adult evidence and labeling cannot automatically be transferred to adolescents. Age-appropriate psychotherapy, family participation, nutritional care, and medical assessment remain especially important.
Will medication alone achieve lasting recovery?
A decrease in an individual symptom may be valuable, but comprehensive recovery also involves physical health, psychological functioning, eating flexibility, and relapse prevention. NICE advises against medication as the sole treatment for anorexia, bulimia, or BED.
When is medical care urgent?
Urgent assessment is warranted for fainting, chest pain, severe dehydration, serious palpitations, profound weakness, confusion, suspected electrolyte problems, overdose, or suicidal crisis. Serious illness can occur across the weight spectrum, including in atypical anorexia. Clinical evaluation takes precedence over outpatient medication adjustments.
Related Articles
Eating Disorder Treatment: Evidence-Based Therapies and Care explains psychotherapy, nutrition, and levels of treatment in an integrated plan.
Eating Disorders: Types, Symptoms, Causes, and Treatment provides the parent overview of diagnostic categories and early recognition.
Bulimia Nervosa: Symptoms, Diagnosis, and Treatment explores diagnosis-specific symptoms, medical risks, and multidisciplinary care.
Eating Disorder Recovery: Stages, Challenges, and Support addresses sustainable change, treatment engagement, and ongoing support.
References
American Psychiatric Association. (2023). The American Psychiatric Association practice guideline for the treatment of patients with eating disorders. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.23180001.
Attia, E., Steinglass, J. E., Walsh, B. T., et al. (2019). Olanzapine versus placebo in outpatient adults with anorexia nervosa: A randomized clinical trial. American Journal of Psychiatry, 176(6), 449–456. https://doi.org/10.1176/appi.ajp.2018.18101125.
Costa, G. P. A., Assunção, B. R., Belfort-DeAguiar, R., & Nunes, J. C. (2025). Pharmacotherapies for binge eating disorder: Systematic review and network meta-analysis. Obesity Reviews, 26(9), e13936. https://doi.org/10.1111/obr.13936.
DailyMed. (2026, label accessed October 10). Bupropion hydrochloride extended-release tablets (XL): Prescribing information, contraindications. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98d5977f-9b32-46db-bd36-a2c4d1b0710a.
DailyMed. (2026, label accessed October 10). Fluoxetine capsules: Prescribing information, bulimia nervosa. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70e115cc-6e9b-4b96-a1a9-779ed51ad0a7.
Hodrob, T., Ismail, I., Abusalameh, A., et al. (2026). Efficacy and safety of lisdexamfetamine versus topiramate versus naltrexone/bupropion in individuals with binge eating disorder: A network meta-analysis. European Eating Disorders Review, 34(2), 334–346. https://doi.org/10.1002/erv.70035.
National Institute for Health and Care Excellence. (2017, updated). Eating disorders: Recognition and treatment. NICE guideline NG69. https://www.nice.org.uk/guidance/ng69/chapter/recommendations.
U.S. Food and Drug Administration. (2025). Vyvanse (lisdexamfetamine dimesylate): Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021977s054%2C208510s011lbl.pdf.
World Federation of Societies of Biological Psychiatry Task Force. (2023). WFSBP guidelines update 2023 on the pharmacological treatment of eating disorders. World Journal of Biological Psychiatry. https://doi.org/10.1080/15622975.2023.2179663.